The NIH has decided to cap indirect cost reimbursements for research grants at 15%, down from an average of 27-28%. This policy aims to direct more funds towards essential scientific research rather than administrative overhead, which constituted $9 billion of the $35 billion granted in fiscal 2023. Critics argue this reduction could hinder progress in medical breakthroughs, affecting cancer and chronic disease treatments and jeopardizing the U.S.'s leadership in biomedical innovation. Congress has not acted on similar proposals before, indicating potential political complexities ahead.
The United States should have the best medical research in the world. It is accordingly vital to ensure that as many funds as possible go towards direct scientific research costs rather than administrative overhead.
This action will slow advances for millions of patients who desperately need critical breakthroughs and imperil the U.S.'s position as the world leader in biomedical innovation.
Collection
[
|
...
]